Tags : OAV-101

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program

Tuba Khan August 3, 2021

Shots: The FDA decision to lift the partial clinical trial hold of the OAV-101 IT clinical program is based on data from a nonclinical toxicology study in NHP The company […]readmore

Tags : OAV-101

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : OAV-101

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company